CD10 and CD34 expression in childhood acute lymphoblastic leukemia in morocco: Clinical relevance and outcome

Pediatric Hematology and Oncology

Volumn 26, Issue 4, 2009, Pages 216-231

  Dakka, Nadia ^a   Bellaoui, Hicham ^a   Bouzid, Nadia ^a   Khattab, Mohammed ^b   Bakri, Youssef ^a   Benjouad, Abdelaziz ^a  

^a FACULTÉ DES SCIENCES   (Morocco)

^b Hopital d'Enfants   (Morocco)

Author keywords

Acute lymphoblastic leukemia; CD10; CD34; Children; DNA content; Prognostic factors

Indexed keywords

CD34 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CORTICOSTEROID; DNA; MEMBRANE METALLOENDOPEPTIDASE; TUMOR MARKER;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIGEN EXPRESSION; ARTICLE; BLOOD SAMPLING; BONE MARROW CELL; BONE MARROW EXAMINATION; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DISEASE COURSE; DNA CONTENT; FEMALE; FLOW CYTOMETRY; HEMATOLOGICAL PARAMETERS; HEPATOMEGALY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; INFANT; KAPLAN MEIER METHOD; LEUKEMIA CELL; LEUKOCYTE COUNT; LYMPHADENOPATHY; MALE; MEDIASTINUM MASS; MOROCCO; PROGNOSIS; RELAPSE; REMISSION; SPLENOMEGALY; SURVIVAL RATE; TREATMENT OUTCOME; ADOLESCENT; B LYMPHOCYTE; FOLLOW UP; IMMUNOLOGY; MORTALITY; PRESCHOOL CHILD; T LYMPHOCYTE;

ADOLESCENT; ANTIGENS, CD34; B-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; KAPLAN-MEIERS ESTIMATE; MALE; MOROCCO; NEPRILYSIN; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SURVIVAL RATE; T-LYMPHOCYTES; TUMOR MARKERS, BIOLOGICAL;

EID: 67651171388     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.1080/07357900902897557     Document Type: Article

References (47)

1. Vidriales MB, San-Miguel JF, Orfao A, et al. Minimal residual disease monitoring by flow cytometry. Best Practice & Res Clin Haematol. 2003;16:599-612.
2. Letarte M, Vera S, Tran R, et al. Common acute lymphoblastic leukemia antigen is identical to neutral endopeptidase. J Exp Med. 1988;168:1247-1253.
3. Cossman J, Neckers LM, Leonard WJ, et al. Polymorphonuclear neutriphils express the common acute lymphoblastic leukemia antigen. J Exp Med. 1983;157:1064-1069.
4. Ludwig WD, Haferlach T, Schoch C. Classification of Acute Leukemias. In: Pui, CH, ed. Treatment of Acute Leukemias. New Directions for Clinical Research. Totowa, NJ: Humana Press; 2003:3-41.
5. Lanza F, Healy L, Sutherland DR. Strucural and functional features of the CD34 antigen: an update. J Biol Regul Homeost Agents. 2001;15:1-13.
6. Simmons PJ, Torok-Storb B. CD34 expression by stromal precursors in normal human adult bone marrow. Blood. 1991;78:2848-2853.
7. Pui CH, Rivera GK, Hancock ML, et al. Clinical significance of CD10 expression in childhood acute lymphoblastic. Leukemia. 1993;7:35-40.
8. Pui CH, Hancock ML, Head DR, et al. Clinical significance of CD34 expression in childhood acute lymphoblastic leukemia. Blood. 1993;82:889-894.
9. Rivera-Luna R, Cardenas-Cardos R, Leal-Leal C, et al. B-lineage acute lymphoblastic leukemia of childhood. An institutional experience. Arch Med Res. 1997;28:233-239.
10. Pui CH, Willliams DL, Raimondi SC, et al. Unfavorable presenting clinical and laboratory features are associated with CALLA-negative non-T, non-B lymphoblastic leukemia in children. Leukemia Res. 1986;10:1287-1292.
11. Vannier JP, Bene MC, Faure GC, et al. Investigation of the CD10 (CALLA) negative acute lymphoblastic leukaemia: further description of a group with a poor prognosis. Br J Haematol. 1989;72:156-160.
12. Pui CH, Crist WM. High risk lymphoblastic leukemia in children: prognostic factors and management. Blood Rev. 1987;1:25-33.
13. Basso G, Rondelli R, Putti MC, et al. Incidence and prognostic significance of immunophenotypic subgroups in childhood acute lymphoblastic leukemia: the experience of the AIEOP cooperative study. In: Ludwig WD, Thiel E, eds. Recent Results in Cancer Research. Berlin: Springer; 1993:297-307.
14. Consolini R, Legitimo A, Rondelli R, et al. Clinical relevance of CD10 expression in childhood ALL. Haematologica. 1998;83:967-973.
15. Borowitz MJ, Shuster J, Curt I, et al. Prognostic significance of CD34 expression in childhood B-precursor acute lymphocytic leukemia: a pediatric oncology group study. J Clin Oncol. 1990;8:1389-1398.
16. Vanhaeke DR, Bene MC, Garand R, et al. Expression and long-term prognostic value of CD34 in childhood and adult acute lymphoblastic leukemia. Leukemia Lymphoma. 1995;20:137-142.
17. Hrusak O, Porwit-MacDonald A. Antigen expression patterns reflecting genotype of acute leukemias. Leukemia. 2002;16:1233-1258.
18. WHO. Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.
19. Schabath R, Ratei R, Ludwig W-D. The prognostic significance of antigen expression in leukemia. Best Practice Res Clin Haematol. 2003;16:613-628.
20. Baruchel A, Leverger G, Schaison G. Use of immunophenotype as part of the prognostic stratification for childhood ALL in the FRALLE 93 protocol. Leukemia Lymphoma. 1994;13 (Suppl 1):91-93.
21. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976;33:451-458.
22. Bennett JM, Catovsky D, Daniel MT, et al. the FAB Cooperative Group. The morphological classification of acute lymphoblastic leukaemia: concordance among observers and clinical correlations. Br J Hematol. 1981;47:553-561.
23. Owens MA, Vall HG, Hurley AA, et al. Validation and quality control of immunophenotyping in clinical flow cytometry. J Immunol Methods. 2000;243:33-50.
24. Béné MC, Castoldi G, Knapp W, et al. Proposal for immunological classification of acute leukemias. European Group for the Immunological Characterisation of Leukaemias (EGIL). Leukemia. 1995;9:1783-1786.
25. Dakka N, Bellaoui H, Khattab M, et al. Immunological profile and outcome of childhood acute lymphoblastic leukemia (ALL) in Morocco. J Pediatr Hematol Oncol. 2007;29:574-580.
26. Schaison G, Leverger G, Bancillon A, et al. Intermediate risk childhood acute lymphoblastic leukemias: amsacrine+cytosine arabinoside versus intermediate dose methotrexate for consolidation, and 6- mercaptopurine+methotraxate+vincristine versus monthly pulses for maintenance. Haematol Blood Transfus. 1987;30:461-465.
27. Schaison G, Auclerc MF, Baruchel A, et al. Prognosis of acute lymphoblastic leuemiain children: results of the French protocol FRALLE 93. Bull Acad Natl Med 2001;185:149-66.
28. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53:457-481.
29. Schrappe M, Stanulla M. Treatment of childhood acute lymphoblastic leukaemia. In: Pui CH, ed. Treatment of Acute Leukemias. New Directions for Clinical Research. Totowa, NJ: Humana Press; 2003:87-104.
30. Pui CH, Behm FG, Crist WM. Clinical and biological relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood. 1993;82:343-362.
31. Hann IM, Richards SM, Eden OB, et al. Analysis of the immunophenotype of children treated on the Medical Research Council United Kingdom Acute Lymphoblastic Leukemia Trial XI (MRC UKALLXI). Medical Research Council Childhood Leukaemia Working Party. Leukemia. 1998;12:1249-1255.
32. + subpopulation of leukemia cells. Leukemia. 2003; 17:2130-2139.
33. Thomas X, Archimbaud E, Charrin C, et al. CD34 expression is associated with major adverse prognostic factors in adult acute lymphoblastic leukemia. Leukemia. 1995;9:249-253.
34. Van Wering ER, Van Der Linden-Shrever BE, Szczepanski T, et al. Regenerating normal B-cell precursors during and after treatment of acute lymphoblastic leukaemia: implications for monitoring of minimal residual disease. Br J Haematol. 2000;110: 139-146.
35. Basso G, Lanza F, Orfao A, et al. Clinical and biological significance of CD34 expression in acute leukemia. J Biol Regul Homeos Agents. 2001;15:68-78.
36. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996;14:18-24.
37. Pui CH, Campana D, Evans WE. Childhood acute lymphobastic leukaemia: current status and future perspectives. Lancet Oncol. 2001;2:597-607.
38. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med. 2004;350:1535-1548.
39. Ludwig WD, Haferlach T, Schoch C. Classification of acute leukemias: perspective I. In: Pui CH, ed. Treatment of Acute Leukemias. New Directions for Clinical Research. Totowa, NJ: Humana Press; 2003:3-41.
40. Raimondi SC, Zhou Y, Mathew S, et al. Reassessment of the prognostic significance of hypodiploidy in pediatric patients with acute lymphoblastic leukemia. Cancer. 2003;98:2715-2722.
41. Talby L, Chambost H, Roubaud M-C, et al. The chemosensitivity to therapy of childhood early B acute lymphoblastic leukemia could be determined by the combined expression of CD34, SPI-B and BCR genes. Leukemia Res. 2006;30:665-676.
42. Coustan-Smith E, Ribeiro RC, Stow P, et al. A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome. Blood. 2006;108:97-102.
43. Lucio P, Parreira A, Van Den Neemd MW, et al. Flow cytometric analysis of normal B cell differenciation: a frame of reference for the detection of minimal residual disease in preB-ALL. Leukemia. 1999;13:419-427.
44. Weir EG, Cowan K, Lebau P, Borowitz MJ. A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal Bprecursors with four colorflow cytometry: implications for residual disease detection. Leukemia. 1999;13:558-567.
45. Campana D, Coustain Smith E. Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry. 1999;38:139-152.
46. Howard SC, Pedrosa M, Lins M, et al. Establishment of a pediatric oncology program and outcomes of childhood acute lymphoblastic leukemia in a resource-poor area. JAMA. 2004;291:2471-2475.
47. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166-178.